A new enforcement action from FDA signals that executive podcast appearances can be regulated like traditional ads when ...
Federal health officials posted a warning about misleading statements by biotech billionaire Dr. Patrick Soon-Shiong about ...
Adstiladrin may now be thawed in a water bath following an FDA label update, facilitating more efficient treatment delivery ...
Diagnostic test based on urinary tumor markers hold promise for earlier or prompt detection of bladder cancer in patients ...
Nadofaragene firadenovec-vncg is the only FDA-approved nonreplicating intravesical gene therapy for high-risk ...
Federal health officials posted a warning about misleading statements by biotech billionaire Dr. Patrick Soon-Shiong about ...
Advances in Bladder Cancer: innovation in diagnostics, therapeutic technology, and clinical pathways
Non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) continue to pose significant clinical and health-economic challenges in ...
Relmada Therapeutics Inc (NASDAQ:RLMD) is among the best psychedelic stocks to buy in 2026. The company has several potential ...
Ticker: Fire truck in LaGuardia crash lacked runway warning system; FDA flags misleading claims for cancer drug by biotech ...
Shares of ImmunityBio plummeted Tuesday after the Food and Drug Administration said the biotech company used false or ...
1d
NCCN 2026 Bladder Cancer Guidelines Adopt IBCG Risk Stratification Model for Intermediate-Risk NMIBC
The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results